Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
Recruiting
Observational Study
Alzheimer Disease
FTD
Young-onset Dementia
MCI
Parkinson Disease
ALS (Amyotrophic Lateral Sclerosis)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,200 (estimated)
- Sponsor
- Ospedale Policlinico San Martino · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expressio…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
• Patients suffering from neurodegenerative diseases
Exclusion Criteria
• Patients not suffering from neurodegenerative diseases
Contacts